ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Cardiac

June 27, 2017
Mehaffey and colleagues evaluated major adverse events in 118 cardiopulmonary bypass (CPB) patients who had received methylene blue (MB) within 72 hours of CPB.
June 27, 2017
Balsam and colleagues present two cases of Mycobacterium chimaera infection following implantation of left ventricular assist devices, likely linked to bioaerosols from heater-cooler units used during surgery.
June 26, 2017
The authors analyzed long-term recurrent aortic regurgitation (AR) in 249 patients with aortic insufficiency and reimplantation procedure. Of the cusp repair techniques evaluated in the analysis, only free margin reinforcement and patch repair influenced valve durability, the former positively and the latter negatively.
June 22, 2017
The Amsterdam Investigator-initiated Absorb Strategy All-comers Trial report safety concerns identified in early results for the bioresorbable scaffold drug eluting stent. The scaffold group experienced significantly higher rates of device thrombosis than the stent group (3.5% vs 0.9%; p<0.001).
June 13, 2017
A succinct review of cardiac amyloidosis, particularly relevant to transplant surgeons that are expected to see more patients with the condition
May 6, 2017
He went to Stanford University and got the surgery. Shortly after, Coleman said he wanted to play football again. “Right after surgery, I put two and two together,” Coleman said. “If I’m fixed, I can play football again, right?”
April 28, 2017
Stephen Westaby speaks out on the BBC about the state of cardiac surgery in the NHS in the UK in 2017 
January 27, 2017
CTSNet published over 200 pieces of educational content in 2016. CTSNet Deputy Editor Arie Blitz presents his choices for the most interesting CTSNet content of last year.
January 13, 2017
With the everpresent question of potentially extending LVAD therapy to ambulatory patients with advanced heart failure, the authors--using a Markov model--projected the incremental cost-efffectiveness ratio (ICER) of DT LVADs in this population as compared to conventional medical therapy.

Pages